Clinical trials: GLP - 1
Non-diabetec Obesity, Obesity (Disorder)
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults.
- Trial name
- NCT07834398
- Testing
- Dulaglutide, Semagludtide, Tirzepatide
- Where
- Saudi Arabia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Physiology
GLP-1 Signaling in Truncally Vagotomized Subjects
Investigation of the importance of vagal signaling for the glucohomeostatic effects of GLP-1. The study will include physiological studies of truncally vagotomized participants and matched controls.
- Trial name
- NCT02940184
- Testing
- Tablet Sitagliptin 100mg (evening before and morning of experiments), Intestinal Fructose administration
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Cardiometabolic Conditions
Effects of N-Acyl Taurines on Incretin Levels in Healthy Subjects
This study is an investigator-initiated, randomised, double-blind, placebo-controlled, cross-over human trial investigating the effect of arachidonoyl-taurine (C20:4-taurine) and oleoyl-taurine (C18:1-taurine) on GLP-1 secretion…
- Trial name
- NAT-INC (NCT07771166)
- Testing
- Arachidonoyl-taurine: First dose at 0 hours, Oleoyl-taurine: First dose at 0 hours, Liquid meal and second dose of OLE-T at 3 hours
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Sexual Desire
Effects of Glucagon-like-Peptide-1 Analogues on Sexuality
This study is to investigate the effects of GLP-1 analogues (combined with lifestyle interventions in comparison to lifestyle interventions only) on sexual desire, mood, quality of life, the reproductive axis, retinal vessel…
- Trial name
- Desire PLUS (NCT05598008)
- Where
- Switzerland
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Obesity, Overweight
A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight
The primary objective of this study is to evaluate the effect of a meal and evening dosing on the pharmacokinetics (PK) of KAI 7535 in healthy participants living with obesity or overweight.
- Trial name
- NCT07294898
- Testing
- KAI-7535
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kailera
Diabetes Mellitus, Type 2
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.
- Trial name
- NCT00537719
- Testing
- GSK716155
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus, PreDiabetes
Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus
This study is conducted to examine GLP-1, insulin resistance and insulin sensitivity portfolio in Malay, Chinese and Indian populations in Malaysia and to study the effect of DPPIV inhibitor in T2DM patients with different…
- Trial name
- GLP-1 (NCT03659461)
- Testing
- Sitagliptin
- Where
- Malaysia
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
Diabetes, Heart Failure
The Effects of Neprilysin on Glucagon-like Peptide-1
In the current study we wish to investigate the effects on glucagon-like peptide-1 (GLP-1) of a neprilysin inhibitor
- Trial name
- NEP (NCT03717688)
- Testing
- Entresto, Sitagliptin 100mg
- Where
- Denmark
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Blood Sugar; High, Overweight and Obesity
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity
- Trial name
- NCT06333496
- Testing
- GLP-1 Booster (GB)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alpine Biotech LLC
Type 2 Diabetes Mellitus
Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus
GLP-1 is an incretin hormone which is discharged from the intestines after food intake. The hormone is known for its powerful insulinotropic and trophic effects on the beta cells in the pancreas and is currently used as an…
- Trial name
- NCT00923962
- Testing
- Glucagon like peptide-1, Adenosine
- Where
- Denmark
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Overweight and Obesity, Healthy
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg twice daily [BID]) or placebo for 5 days beginning on Day 1.
- Trial name
- NCT06500429
- Testing
- NG101, Semaglutide Injectable Product
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Neurogastrx, Inc.
Type 2 Diabetes
A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186
This study will assess the safety, tolerability, and pharmacokinetics of AZD0186 following single ascending doses (SAD) via oral administration in healthy adult participants.
- Trial name
- NCT05694741
- Testing
- AZD0186
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09
JY09 is a glucagon-like peptide-1 (GLP-1) mimetic generated by genetic fusion of a Exendin-4 dimer to human immunoglobulin Fc. In this Double-blind, randomized, placebo-controlled trial, 41 healthy subjects received placebo or…
- Trial name
- NCT04354090
- Testing
- JY09
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
Obesity
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.
- Trial name
- NCT04186026
- Testing
- Saline + saline, Neurotensin + saline, GLP-1 + saline
- Where
- 2 sites in Denmark
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Type 2 Diabetes Mellitus
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
Incretinbased treatment of patients with type 2 diabetes mellitus (T2DM) has increasing interest. The incretin glucagon-like peptide-1 (GLP-1) stimulates beta-cells to increased secretion and production of insulin.
- Trial name
- NCT00655603
- Testing
- Infusion of native hormones from the pancreas and gut (GLP-1)
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Glucagon-like Peptide-1, Smoking Cessation
Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues
Cigarette smoking is the leading preventable cause of premature death worldwide. However smoking is a very difficult addiction to break whereby main reasons for not quitting or relapsing after cessation are the nicotine…
- Conditions
- Glucagon-like Peptide-1, Smoking Cessation, Weight Change, Body, Craving
- Trial name
- SKIP (NCT03204396)
- Testing
- Dulaglutide, 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])
- Where
- Switzerland
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion
The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion
The last couple of years it has been shown that bile acids not only acts as simple emulsifiers of fat, but constitutes a complex metabolic integrator which not only have an influence on fat digestion and lipid metabolism, but…
- Trial name
- NCT01656057
- Testing
- Acetaminophen, Metformin, Colesevelam
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Filip Krag Knop
Postural Orthostatic Tachycardia Syndrome (POTS), Healthy
POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS
This study will describe the interplay between the gut hormones GIP and CCK and their regulation of blood flow to the large vessels in patients with Postural Orthostatic Tachycardia Syndrome (POTS) and GIP, CCK and GLP-1 in…
- Trial name
- GA22 (NCT07019519)
- Testing
- GIPR antagonist, GLP-1R antagonist, CCK agonist
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Digestive Physiology, Gastrointestinal Motility
Effects of Exendin(9-39) on Gastroduodenal Motility
The purpose of this study in humans is to define the effects of the endogenous hormone GLP-1 on gastroduodenal motility and on endocrine pancreatic secretion by using the specific GLP-1 receptor antagonist exendin(9-39).
- Conditions
- Digestive Physiology, Gastrointestinal Motility, Gastrointestinal Hormones, Glucagon-like Peptide 1
- Trial name
- NCT00468091
- Testing
- exendin(9-39)amide, atropine
- Where
- Germany
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Vagotomy, Truncal
Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects
The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of Glucagon-like peptide-1 (GLP-1) in respect to gastric emptying, appetite and food intake.
- Trial name
- NCT01176890
- Testing
- GLP-1, Saline
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen